Our study aims to investigate and describe the epidemiology of the intestinal carriage of ESBL-PS in intensive care units of five Lebanese hospitals and to analyze the potential risk factors for the acquisition of these strains. At the same time, we intend to determine the patterns of susceptibility of these strains, exploring therefore the availability of alternative treatment. One thousand, four hundred forty-two fecal samples were collected between January 1, 2003 and March 31, 2003 from 378 patients admitted to the ICUs of five Lebanese tertiary care general hospitals located in different areas of Lebanon. ESBL production was detected by the double disk synergy test and antibiotic susceptibility of ESBL-producing strains as well as minimum inhibitory concentrations were determined. A paired case-control study was undertaken to identify risk factors for carriage of ESBL-PS. One hundred eighteen strains isolated from 72 subjects were identified as ESBL producers, including 95 (80.5%) E. coli, 16 (13.6%) Klebsiella pneumoniae, and 7 (5.6%) Enterobacter cloacae. A higher rate of multiple ESBL-PS carriage was described among these acquisition cases (21 double carriages and 3 triple carriages of ESBL-PS compared to only 1 double carriage of ESBL-PS at admission). In general, similar trends of susceptibility were observed in the different hospitals. As expected, the lowest MIC was observed with imipenem for all E. coli, Klebsiella, and Enterobacter isolates. Ciprofloxacin, followed by trimethoprim-sulfamethoxazole seem to be associated with the lowest susceptibility. In vitro susceptibility to cefoxitin for all isolates was 74.6%; more resistance was associated to ceftazidime (90.7%) than to cefotaxime (69.7%). Our data agree with other national and international reports showing the increase in ESBL-PS carriage in ICU patients. They demonstrate the endemic character of this carriage in Lebanese hospitals and the important risk factors including immunosuppression and evidence of ESBL infection. The highly resistant profile of ESBL-PS to antimicrobial agents available for treatment reflects the severity of this issue. The significance of this study resides in the direct correlation between our results and the nationwide increase in multi-drug resistant bacteria and the continuous change in bacterial resistance epidemiology. Our data may have an important impact on infection control policies in hospitals and on treatment of infectious diseases.
Introduction
Extended-spectrum b-lactamases (ESBLs) are enzymes that confer resistance to penicillins, narrowand extended-spectrum cephalosporins, monobactams and related oxyimino-b-lactams (ceftazidime, cefotaxime) and have been shown to be inactive against cephamycins and carbapenems (Bradford, 2001; Bradford et al., 1994; Bush et al., 1995; Pitout and Sanders, 1997) . Clavulanate, tazobactam and other blacamase inhibitors are generally effective against ESBLs although some inhibitor resistant variants have been described (Bradford, 2001; Bradford et al., 1994; Bush et al., 1995) . Bacteria producing ESBLs are most commonly Klebsiella pneumoniae and Escherichia coli, as well as other members of the genus in Enterobacteriaceae (Jarlier et al., 1998) .
In Lebanon, a study done at a general hospital in Beirut in 1998 (Araj, 1999) revealed that the prevalence of ESBL-producing E. coli and K. pneumoniae isolates was 3.3% and 6.4%, respectively. At Saint George University Hospital, a 300-bed hospital participating in our study, 2% of 4,299 isolates of E. coli and 20% of 1,248 isolates of K. pneumoniae were found to produce ESBLs between 1997 and 2001 (Daoud and Hakime, 2003) . In fact, the percentage of these had been experiencing a constant rise over the 5 years from 7.5% to 24% for Klebsiella pneumoniae and reached 4% for Escherichia coli (Daoud and Hakime, 2003) .
Numerous ESBL enzymes have been described, with greater than 100 in the TEM class, over 40 in the SHV family, over 30 in the CTX-M class, and 15 in the OXA family (Bonnet, 2004; Bradford, 2001) . These enzymes are coded by plasmids which may also carry resistance to other antibiotics, including aminoglycosides, tetracyclines, chloramphenicol, trimethoprim, and sulfonamides (Bush et al., 1995) . Molecular characterization of strains isolated in a nationwide project from which this study is derived showed that 83% produced the CTX-M-15 variant of ESBL enzymes (Daoud et al., 2005) . SHV-5a was detected in the remaining isolates. Although most ESBL variants are of the TEM type, these were not detected in this study (Daoud et al., 2005) . Pulse field gel electrophoresis (PFGE) phenotypes of E. coli producing ESBL enzymes were highly diverse. Patient transfer between hospitals is commonly practiced in Lebanon and might have been the impetus for the spread of resistancecarrying plasmids, thereby producing this diversity in phenotypes.
In 2002, as reported by the Center for Disease Control and Prevention, 6.3% of Escherichia coli, 14% of Klebsiella pneumoniae, and 32.2% of Enterobacter spp. were resistant to third generation cephalosporins in intensive care units in the United States (Hacek et al., 2001; Kaye et al., 2004; National Nosocomial Infections Surveillance System Report, 2003) . Across Europe, on the other hand, ESBL production varies hugely and the percentage of ceftazidime resistant K. pneumoniae was 20% in non-ICU units and doubled in ICUs before 2001 (Bradford, 2001) . In a study done at Saint George Hospital in Lebanon, around 1/3 of the 89 ESBL-producing isolates of E. coli and 244 of those of K. pneumoniae were from patients admitted to the intensive care unit (Daoud and Hakime, 2003) . Furthermore, the number of ESBL-positive E. coli and K. pneumoniae was undergoing a constant increase until 2001 in ICUs as well as elsewhere (Daoud and Hakime, 2003) .
Information about the epidemiology of ESBL-producing bacteria in Lebanon is still limited, particularly their occurrence in ICUs. Health care facilities are increasingly reporting outbreaks of these organisms challenging their infection control units. Our study aims to examine the fecal carriage of ESBL-producing bacteria in patients admitted to intensive care units of five hospitals in Lebanon over a 3-month period.
Materials and Methods
Study design. This study is a prospective surveillance study in which fecal samples collected from hospitalized patients and health care personnel were screened for the presence of possible ESBL-producing strains (ESBL-PS Bacterial strains. All samples were suspended at participating sites in normal saline in order to form a 10 mg/ml suspension. From these, 100 ml were streaked on Trypticase soy-5% sheep blood agar containing 6 mg/ml of vancomycin, 2 mg/ml of amphotericin B, 2 mg/ml of ceftazidime and 1 mg/ml of clindamycin (VACC medium) (Hacek et al., 2001) . After 24 and 48 h of incubation at 35°C, colonies appearing on the plates were sent to the Saint George Hospital collecting laboratory for strain identification by the API 20E system (bioMérieux) and for resistance phenotype analysis and minimum inhibitory concentration (MIC) determination.
Antibiotic susceptibility testing and ESBL detection. ESBL production was detected by the double disk synergy test according to the method described by Jarlier et al. (1988) . Ceftazidime (30 mg), cefepime (30 mg), aztreonem (30 mg) and cefotaxime (30 mg) disks (Oxoid) were placed 25 mm (center to center) from the amoxicillin/clavulanic acid (20/10 mg) disk on MuellerHinton agar plate inoculated with the test organism. After overnight incubation, enhancement of the inhibition zone around one of these disks toward the clavulanate-containing disk indicated the presence of ESBLs. Antibiotic susceptibility of ESBL-PS was determined by the disk diffusion method according to the recommendations of the National Committee of Clinical Laboratory Standards (NCCLS) (2000) . The following disks were tested: amoxicillin/clavulanic acid (20 mg/10 mg), cefoxitin (30 mg), cefotaxime (30 mg), ceftazidime (30 mg), gentamicin (10 mg), trimethoprim/ sulfamethoxazole (1.25 mg/23.75 mg), amikacin (10 mg), and imipenem (10 mg). The minimum inhibitory concentrations (MIC) of imipenem, cefoxitin, ceftriaxone, cefepime, gentamicin, amikacin, amoxicillin/clavulanic acid, piperacillin/tazobactam, aztreonam, ciprofloxacin, and ceftazidime, and cefotaxime (with and without clavaulanate) were determined by using the E-test (AB-Biodisk). For each subject, if several ESBL-producing isolates were detected and all were from the same species and presented similar antibiograms, only one was selected for further study and the others were considered to be repetitive isolation of the same strain.
Epidemiological survey. The time for ESBL producing Enterobacteriaceae acquisition was defined for each of the 41 patients from whom no ESBL-PS were isolated at admission by taking into account the date on which the patient entered the ICU and the date on which the strain was isolated from the patient's fecal material. Only new acquisitions were considered and the isolation of an ESBL-PS from the same patient was considered a new acquisition if it was preceded by at least one negative sample.
A paired case-control study was undertaken to identify risk factors for carriage of ESBL-PS using the SPSS 11.0 software. It covered the whole period of the study and involved 59 patients from which 68 ESBL-PS were newly isolated (after admission) including patients who were not colonized at admission and patients who were recolonized after eradication of the ESBL-PS (41ϩ18 patients respectively). This does not take into consideration the number of ESBL-PS newly isolated from the same patient at the same time, but considers the acquisition as a fact regardless of the number of strains. Each of these 59 patients was matched with a control hospitalized in the same unit and from whom ESBL producing strains were never isolated. The matching was based on gender and the presence of the control in the unit at least 1 week before and 1 week after the date on which the strain was isolated. Parameters covered by the survey questionnaire are indicated in Table 1 . After data collection from the hospitalization reports, univariate analysis of risk factors was performed using student's t-test for comparision of means and c 2 test (nϾ5) with MantelHaenszel weighting for other variables. p-values of Ͻ0.05 were considered significant.
Results
A total of 1,442 fecal samples were collected during the whole study period from 378 ICU patients of the participating 5 hospitals. One hundred eighteen strains isolated from 72 subjects were identified as ESBL producers including 95 (80.5%) E. coli, 16 (13.6%) Klebsiella pneumoniae and 7 (5.6%) Enterobacter cloacae. These were detected in all participating hospitals as follows: SGH (52 isolates), SJH (22 isolates), AH (20 isolates), RH (17 isolates) and NN (7 isolates). The characteristics of the enrolled admissions are represented in Table 1 .
Thirty one patients, from whom 32 ESBL-PS were isolated, were considered as imported cases since carriage was positive at the time of admission. Among these, only one patient was noted for the carriage of more than one ESBL producing isolate. On the other hand, 41 new patients, for whom a conversion from negative carriage at ICU admission to positive carriage after admission was noted, in addition to 18 patients who were previously colonized (at admission) then recolonized after at least 48 h of ESBL-PS eradication, were considered as acquisition cases (a total of 59 patients and 86 isolates). A higher rate of multiple ESBL-PS carriage was described among these acquisition cases (21 double carriages and 3 triple carriages of ESBL-PS compared to only 1 double carriage of ESBL-PS at admission). Figure 1 shows the distribution of carriage of ESBL-PS over the different time periods of ICU stay. The data here show the actual state of carriage during a specific time interval. It is obvious that there is a clear decrease in carriage after admission to ICU in SGH, SJH, and NN hospitals, while in AH and RH hospitals the highest percentage of carriage is observed after 72 h. In all hospitals, a sharp decrease in carriage is observed after 72 h and up to 2 weeks of ICU stay. In SGH and SJH an increase is re-observed after 15 days.
Antimicrobial susceptibility testing by the disk diffusion method indicated strong synergy between amoxicillin-clavulanate and either cefotaxime or ceftazidime observed in 103 (87.3%) cases. All ESBL-PS were resistant to extended spectrum cephalosporins (MIC 90 s for E. coli, Klebsiella, and Enterobacter were all greater than 256 mg/ml for ceftazidime. The MIC 90 of E. coli to cefotaxime was 96 mg/ml and that of Klebsiella and Enterobacter was greater than 256 mg/ml. In the disk diffusion method, all the tested isolates showed resistance to at least one of either ceftazidime or cefotaxime ( Table 2 ). Strains that showed in vitro resistance to both antimicrobial agents did not exceed 10% (data not shown). All isolates were susceptible to imipenem. In the presence of 2 mg/ml of clavulanic acid the susceptibility of these strains to ceftazidime and/or cefotaxime was restored. Table 3 shows the patterns of susceptibility of the ESBL-PS to different antimicrobial agents. In general, similar trends of susceptibility were observed in the different hospitals. Exceptions were noted for susceptibility to piperacillin/tazobactam in SGH and AH hospitals (showing lower percentages of susceptibility in comparison to other hospitals) and for gentamicin, ciprofloxacine, and trimethoprim-sulfamethoxazole at NN hospital, where the percentages of susceptibility to these antibiotics were significantly increased in comparison to other hospitals.
The best susceptibility was associated with amikacin with values ranging between 71.4 and 92%.
Ciprofloxacin, followed by trimethoprim-sulfamethox- azole seem to be associated with the lowest susceptibility (0 to 10% for ciprofloxacine and 9.5 to 50% for trimethoprim-sulfamethoxazole) excluding NN hospital in both cases.
In vitro susceptibility to cefoxitin for all isolates was 74.6% (88 strains). More in vitro resistance was associated to ceftazidime (90.7%) than to cefotaxime (69.7%). Table 4 shows the different MICs of the ESBL-PS towards the tested antibiotics. As expected, the lowest MIC, reflecting the best antibacterial effect, was observed with imipenem for all E. coli, Klebsiella, and Enterobacter isolates. Similar patterns of susceptibility and MIC values with normal variations were observed among these different genera.
Discussion
The consequences of infection with ESBL producing Enterobacteriaceae can be severe and lead to serious complications. The situation is made worse when such infections occur in critically ill patients in the ICU, where medical manipulations are frequent and antibiotic use is massive (Itokazu et al., 1996) .
It has been demonstrated that infection due to highly resistant microorganisms is frequently associated with previous body site colonization (Nseir et al., 2005) .
In this context, this multiple center study shows that the stay in the ICU affects significantly the occurrence of ESBL-PS carriage in patients. The results of surveillance cultures at ICU entry, and discharge as well as during ICU stay show that the overall number of patient carriers of ESBL-PS was increased by approximately twofold and that the number of ESBL-PS that were acquired during the course of ICU admission was approximately increased by threefold. The univariate analysis of risk factors strongly correlates the cases of ESBL-PS carriage with the evidence for infection with this class of bacteria, immunosuppressive factors, and both general and abnormal surgery. This agrees with many previous studies that highlighted the importance of colonization pressure on the risk of acquisition of resistant bacteria (D'Agata et al., 1999; Merrer et al., 2000; Nseir et al., 2005; Toltzis et al., 1997) . A thorough analysis of the changes occurring in ESBL-PS carriage during ICU stay (Fig. 1) shows that an aver- (35) 64 (32) 10 (5) 22 (11) 92 (46) 32 (16) 6 (3) I 4 (2) 10 (5) 0 (0) 4 (2) 0 (0) 6 (3) 4 (2) 6 (3) R 30 (15) 20 (10) 36 (18) 86 (43) 78 (39) 2 (1) 64 (32) 88 (44) SJH (nϭ21 NN ( All isolates were susceptible to imipenem. SGH, Saint George Hospital; SJH, Saint Joseph Hospital; AH, Arz Hospital; RH, Rizk Hospital; NN, Nini Hospital.
age of 30 to 40% of the isolated strains are observed on the day of admission; this is observed in all the hospitals with the only exception of AH hospital. After admission, the following 72 h seem to be associated with the highest percentage of acquisition of ESBL-PS during ICU stay. This is true with all involved hospitals including SGH and SJH, where 36% and 25% of the isolates occurred after 15 days of ICU stay respectively. This is explained by the fact that the average length of stay in ICU is 13 to 15 days; therefore, the re-increase in carriage in these two hospitals is taking place after discharge from the ICU. The fact that the occurrence of ESBL-PS decreases after 72 h and up to 15 days may be explained by the heavy and systematic use of carbapenem antibiotics in the ICUs of these hospitals, and by the emergence of some strains of imipenem-resistant Pseudomonas aeruginosa and Stenotrophomonas maltophilia in the fecal material of the same patients (data not shown).
Another fact that requires special attention is that the acquisition of new ESBL-PS when compared to imported cases seems to be more diverse and is complicated by the multiple-carriage of resistant strains (21 double carriages and 3 triple carriages of ESBL-PS versus only one double carriage in the 31 imported cases).
Our data show that although the acquisition of ESBL-PS follows a decreasing pattern with the length of ICU stay, it becomes more complex and the total number of acquisitions reaches almost double that of importations. Similar results have been described with other studies addressing ceftazidime-resistant gram negative bacilli intestinal carriage (Ho, 2003) ; however, the dynamic evolution of carriage could not be described in that study because the screening was done only at the admission and discharge. In all cases, the use of carbapenems is playing an important role in our study through the selective pressure exerted on the patient's normal intestinal flora.
Preexisting colonization of antibiotic-resistant organisms among ICU patients has implications for the choices of empirical therapy. In cases where ESBL-PS has become prevalent, the adequacy of 3rd generation cephalosporins as empirical antibiotics for serious gram negative infections in critically ill patients has been put in doubt. Carbapenems and piperacilline/ tazobactam became the systematic alternative agents (Babini and Livemore, 2000; D'Agata et al., 1999) .
Excessive antibiotic use in the different wards of hospitals, mainly in the ICU, has been associated with the emergence of b-lactam-resistant enteric bacilli (Babini, 2000; Babini and Livemore, 2000; Masterton, 2000; Monnet, 2000; Waterer and Wunderink, 2001) . The fact that the majority of these isolates (nϭ95) were Escherichia coli followed by Klebsiella pneumoniae (nϭ16) and Enterobacter spp. (nϭ7) is in agreement with previous Lebanese data and international studies (Araj, 1999; Daoud and Hakime, 2003; Masterton, 2000) ; however, it may be contradictory to other surveys (Mulvey et al., 2004; Munday et al., 2004a, b) . The non-interpreted antimicrobial activities of the 3rd generation cephalosporins allows us to study the phenotype of resistance and reveals that susceptibility to ceftazidime (9.3%) is lower than that to cefotaxime (30.5%) in the studied populations. Due to the large number of samples analyzed (nϭ1,882), only one selective medium, including ceftazidime rather than cefotaxime, was chosen according to previous phenotypic results revealing a higher percentage of resistance to ceftazidime than to cefotaxime among ESBL-PS in Lebanon. Moreover, ceftazidime was reported as the best single test antibiotic for the detection of ESBL production (Martin et al., 1996) . Nevertheless, the medium used may have failed to detect some ESBLs and our results may thus underestimate the spread of other ESBL types.
The antimicrobial susceptibility patterns of the isolated ESBL strains show consistency among the different medical centers involved in this study. This was expected in view of the small population of Lebanon, the easy and frequent transfer of patients between areas and hospitals, and the similar medical and therapeutical practices. The higher susceptibility of NN hospital isolates to gentamicin, ciprofloxacin, and trimethoprimsulphametoxazole may be explained by the low number of isolates (nϭ7) or may be due to a different epidemiology taking into account that this hospital is located in the north of Lebanon, while the other hospitals are closer to the capital, Beirut. The minimum inhibitory concentrations clearly show that imipenem is still the most effective drug against ESBL-PS. To our knowledge, resistance has never been reported in Lebanon to this antibiotic among Enterobacteriacae. A significant emergence of imipenem resistant Acinetobacter baumanii and Pseudomonas aeruginosa seems to be an important consequence of carbapenem use in our ICUs (data not shown). Other than imipenem and among the clinically used antibiotics, amikacin and piperacilline/tazobactam are associated with a higher % of susceptibility.
Our results highlight the increasing occurrence of ESBL-PS in the ICU environment of Lebanese hospitals, showing the serious endemicity of this issue. On the other hand, it shows clearly that limited therapeutical alternatives are available for the treatment of infections produced by ESBL-PS. This is alarming for Infection Control Units in Lebanese hospitals and medical centers. 
